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ABSTRACT
Machine learning (ML) has the potential to
improve the dermatologist’s practice from
diagnosis to personalized treatment. Recent
advancements in access to large datasets (e.g.,
electronic medical records, image databases,
omics), faster computing, and cheaper data
storage have encouraged the development of
ML algorithms with human-like intelligence in
dermatology. This article is an overview of the
basics of ML, current applications of ML, and
potential limitations and considerations for
further development of ML. We have identified
five current areas of applications for ML in
dermatology: (1) disease classification using
clinical images; (2) disease classification using
dermatopathology images; (3) assessment of
skin diseases using mobile applications and
personal monitoring devices; (4) facilitating
large-scale epidemiology research; and (5) pre-
cision medicine. The purpose of this review is to
provide a guide for dermatologists to help
demystify the fundamentals of ML and its wide
range of applications in order to better evaluate
its potential opportunities and challenges.
Keywords: Artificial intelligence; Convolutional
neural network; Deep learning; Dermatology;
Image classification; Machine learning; Mobile
applications; Personal monitoring devices;
Precision medicine
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Key Summary Points
Machine learning (ML) has the potential
to improve the dermatologist’s practice
from diagnosis to personalized treatment.
This review article is a guide for
dermatologists to help demystify the
fundamentals of ML and its wide range of
applications in order to better evaluate its
potential opportunities and challenges.
We have identified five current areas of
applications for ML in dermatology: (1)
disease classification using clinical images;
(2) disease classification using
dermatopathology images; (3) assessment
of skin diseases using mobile applications
and personal monitoring devices; (4)
facilitating large-scale epidemiology
research; and (5) precision medicine.
While ML models are powerful,
dermatologists should be cognizant of the
potential limitations of ML (e.g.
algorithmic bias and black box nature of
ML models) and how to make these
technologies inclusive of skin of color.
Involving more dermatologists in the
development and testing of ML models is
imperative for creating useful and
clinically relevant technology.
INTRODUCTION
In dermatology and medicine at large, the
abundance of data in clinical records, patient
demographic information, results from imaging
examinations, and data collected from ques-
tionnaires represent a wealth of information
that has the potential to revolutionize person-
alized medicine [1]. Translational research in
dermatology is already abundant, with data
from the genome, epigenome, transcriptome,
proteome, and microbiome, areas of research
that are often referred to by the shortened term
‘‘omics’’ [2]. Recent advancements in faster
processing and cheaper storage have allowed for
the development of machine learning (ML)
algorithms with human-like intelligence that
have numerous applications in dermatology
[3–5]. To assess the effectiveness of these
emerging technologies, it is imperative that
dermatologists have a basic understanding of
artificial intelligence and ML. In this review, we
first provide an overview of artificial intelli-
gence and ML and how algorithms are devel-
oped. Second, we examine the current
applications of ML that are relevant to derma-
tologists. Lastly, we explore potential challenges
and limitations for the future development of
ML. This review is a guide for dermatologists to
help demystify the fundamentals of ML and its
wide range of applications in order to better
evaluate its potential opportunities and
challenges.
METHODS
This review is based on a literature search per-
formed in Medline, Embase, and Web of Science
databases of articles pertaining to artificial
intelligence and ML in dermatology. The search
was conducted in December 2019. Articles from
2000 to 2019 were included to focus on
emerging methods. Only articles written in
English were included, and articles that were
repeated were excluded. The following primary
keywords were used: ‘‘artificial intelligence,’’
‘‘machine learning,’’ and ‘‘dermatology.’’ After
the preliminary results were reviewed, the Boo-
lean operators ‘‘AND’’ and ‘‘OR’’ were used with
the following secondary keywords: ‘‘personal-
ized medicine,’’ ‘‘teledermatology,’’ ‘‘smart-
phone apps,’’ ‘‘skin cancer,’’ ‘‘nonmelanoma
skin cancer,’’ ‘‘melanoma,’’ ‘‘psoriasis,’’ ‘‘atopic
dermatitis,’’ and dermatopathology.’’ Our liter-
ature search yielded a total of 899 articles,
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among which 70 articles were deemed relevant
to this review.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
OVERVIEW OF ARTIFICIAL
INTELLIGENCE AND MACHINE
LEARNING
What is the Difference Between Artificial
Intelligence and Machine Learning?
Artificial intelligence is a branch of computer
science that uses machines and programs to
simulate intelligent human behavior. Artificial
intelligence dates back to the 1950s to Alan
Turing’s question ‘‘Can machines think?’’ [6]. By
the 1970s, software engineers had created
algorithms with explicit rules for computers on
how to process data. However, the heuristics of
human decision making in medicine were not
easy to program into explicit rules.
ML is a tool comprising a subset of artificial
intelligence that enables the goals of artificial
intelligence to be achieved (Fig. 1). Recently,
ML has piqued attention for its broad range of
uses in daily life from personalized online rec-
ommendations for videos and news to self-
driving cars.
ML covers a variety of algorithms and sta-
tistical methods, including logistic regression,
random forest, and deep learning. Although ML
can seem enigmatic at first, it can be deeply
related to traditional statistical models recog-
nizable to most dermatologists.
Machine Learning Approaches
Machine learning approaches can be divided
into three broad categories: supervised learning,
unsupervised learning, and reinforcement
learning [7]. Supervised learning requires a
dataset to be presented as inputs (called fea-
tures) and outputs (called labels) [7]. For exam-
ple, in an algorithm that classifies a pigmented
lesion as a melanoma or benign, images of
pigmented lesions are ‘‘features’’ and the cate-
gorical data of whether it is malignant or benign
are ‘‘labels.’’ The algorithm is first trained with
labeled images of melanoma and benign pig-
mented lesions and then the computer gener-
alizes this information to a new, unseen set of
images of skin. Supervised learning is the most
common type of learning used in dermatology.
In contrast, unsupervised learning only requires
inputs (unlabeled data), and this approach can
identify unknown clusters or anomalies in data
[7]. Reinforcement learning is a hybrid of both
supervised and unsupervised learning which
learns by trial and error and input from the
environment [7]. An example of reinforcement
learning is the algorithm in AlphaGo [8]. Rein-
forcement learning has yet to be explored in
dermatology.
Fig. 1 Artificial intelligence and machine learning.
Machine learning is a type of artificial intelligence. Some
common types of machine learning approaches used in
dermatology include convolutional neural network
(CNN), natural language processing (NLP), support vector
machine, and random forest. Notably, there are many
other possible machine learning approaches that are not
listed and out of the scope of this review
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Machine Learning Algorithms
There are a variety of ML algorithms commonly
used in dermatology. Most ML algorithms are
examples of statistical learning; for example,
some of the most common statistical learning
methods are linear regression, logistic regres-
sion, k-nearest neighbor (k-NN), support vector
machine (SVM), random forest (RF), and natural
language processing (NLP). k-NN is used for data
classification and regression based on the
number of k neighbors [9, 10]. SVMs are used to
classify data by finding a hyperplane to differ-
entiate between groups [11]. RFs generate a
network of random decision trees to find the
most common outcome among all the ran-
domly generated decision trees [12]. NLP ana-
lyzes large bodies of text in order to identify
patterns [13].
Neural Networks and Deep Learning
Deep learning is a subset of ML that uses sta-
tistical and mathematical models to mimic how
neurons process information. Artificial neural
networks (ANNs), or neural networks (NNs), are
based on a collection of connected units (e.g.,
nodes, neurons, or process layers) [14]. ANNs
are inspired by the network of neurons in the
human brain. The neurons, or nodes, that make
up the ANN are organized into linear arrays
called layers [14]. Each node receives inputs
from other connections that have associated
weights [14]. Creating an ANN includes choos-
ing the number of nodes in each layer, the
number of layers in the network, and the path
of the connections among the nodes [14], and
the typical ANN has input layers, output layers,
and hidden layers. ANNs are trained to perform
specific tasks, such as classification, through a
learning process. Learning within ANNs can be
supervised or unsupervised; however, super-
vised learning is more common. In supervised
learning, a training set contains examples of
input targets and output targets [14]. As the
ANN is trained, the weights of the inputs are
adjusted to minimize the error between the
network output and the correct output [14].
Once the network produces the desired outputs
for a series of inputs, the weights are fixed and
the NN can be applied to other datasets [14].
Convolutional NNs (CNNs) are a special
subclass of ANNs that contain one or more
layers called convolutional units (pooling
units). CNNs take in two-dimensional or three-
dimensional inputs which are passed through
multiple hidden layers. An image can be broken
down into motifs, or a collection of pixels that
form a basic unit of analysis. The first few layers
of the CNN compare each part of an input
image against some small sub-image [5]. Each
node is assigned a certain feature (e.g., color,
shape, size, etc.), and the node’s output to the
next layer depends on how much a part of the
image resembles the feature, a process per-
formed by convolution [5]. After these convo-
lutional layers, pooling layers, which are a
standard NN, classify the overall image [5].
CNNs first showed promise for medical image
classification at the historic 2012 ImageNet
Large Scale Visual Recognition (ILSVRC) con-
ference. A CNN, called AlexNet, was trained to
classify 1.2 million images into 1000 different
categories with a top-5 error rate of 15.3%,
which is the percentage of images for which the
correct class was not among the top five pre-
dicted classes [15]. This was the first CNN to
display such a low error rate. Previous image
datasets were relatively small, comprising only
of tens of thousands of images [16–18]. By 2016,
all methods to classify medical images at the
2016 International Symposium on Biomedical
Imaging used CNNs [19].
Another subtype of CNNs is called a region-
based CNN (R-CNN). R-CNN is a type of CNN
that can detect a desired object within an
image. In the case of dermatology, it can detect
the location of cutaneous lesions by combining
region proposal algorithms with CNNs.
Transfer Learning and Ensemble Learning
Transfer learning utilizes the power of a pre-
trained CNN. These pretrained CNNs are often
trained on databases that include millions of
images, so they are able to distinguish images
with much higher accuracy than a CNN that is
only trained on databases of only a few hundred
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or few thousand images. The last fully con-
nected layer of a pretrained CNN is modified
and trained with images for the more specific
classification task. Examples of common pre-
trained CNNs are AlexNet, Google Inception
V3, ResNet-50, Xception, VGG-19, and VGG-16.
This layered architecture allows researchers to
use a pretrained network without its final layer
as a fixed feature extractor for other tasks. The
learning process of a pretrained CNN can be
faster because it relies on previously learned
tasks. Using a pretrained CNN that is trained on
1–2 million images is more accurate than a CNN
that is trained on a smaller number of images of
the more specific classification tasks. Ensemble
learning improves ML results by combining
several models (meta-algorithms) or the power
of multiple of CNNs together [7].
Metrics for Assessment and Validation
of Machine Learning Models
Machine learning models are assessed according
to variety of metrics based on the number of
true positives (TP), true negatives (TN), false
positives (FP), and false negatives (FN) from a
ML prediction. These metrics include sensitivity
[TP/(TP ? FN)], specificity [TN/(TN ? FP)], pos-
itive predictive value [TP/(TP ? FP)], negative
predictive value [TN/(TN ? FN)], and accuracy
[(TP ? TN)/(TP ? TN ? FP ? FN)]. ML models
are also evaluated on the area under the receiver
operating characteristic (AUROC or AUC). The
receiver operating characteristic (ROC) curve is
calculated by plotting the sensitivity versus
1-specificity [20]. The further the ROC curve
deviates from the diagonal and the larger the
AUROC, the better the algorithm. An AUROC of
1.0 indicates perfect classification, and an
AUROC of 0.5 indicates classification that is no
better than random chance.
Another important metric is the generaliz-
ability of an ML model, or how well a ML model
can learn concepts and apply these concepts to
examples the model has never seen before [21].
There are two terms to describe the generaliz-
ability of an ML model: overfitting and under-
fitting. Overfitting occurs when a ML model
represents the training dataset too well by
capturing the noise of the dataset [7]. Algo-
rithms that are trained and validated with the
same set of images or with the same dataset risk
overfitting to the data. However, current studies
are limited by the images available and may be
trained and validated on images from the same
dataset. Validation or cross-validation to com-
pare the predictive accuracies of datasets can
help prevent overfitting. In contrast, underfit-
ting occurs when a ML model cannot represent
the training dataset and cannot generalize to a
new dataset [7]. Overfitting is more common
than underfitting in ML models.
DERMATOLOGY AND MACHINE
LEARNING
There are many promising opportunities for ML
in the dermatologist’s practice. The classifica-
tion of images through CNN has garnered the
most attention for its potential to increase
accessibility of skin cancer screenings and
streamline the workflow of dermatologists.
CNN has already proven successful in many
other fields, such as ophthalmology, pathology,
and radiology. In 2018, the US Food and Drug
Administration (FDA) approved a CNN in the
IDx-DR diagnostic system (IDx Technologies
Inc., Coralville, IA, USA) [22] for independent
use in diabetic retinopathy screening after being
validated in a pivotal prospective clinical trial of
over 900 patients. This diagnostic system
achieved a sensitivity of 87.2% and specificity of
90.7% and was compared to an independent,
high-quality gold standard of imaging protocols
[23]. However, CNN for the screening of mela-
noma or non-melanoma skin cancers has not
been validated in prospective clinical trials and
still has notable limitations. Beyond the sim-
plistic task of differentiating malignant from
benign lesions, ML can also be applied in dif-
ferential diagnosis, dermatopathology, teleder-
matology, mobile applications, and
personalized medicine. Understanding what
type of deep learning methods are currently
being used and how these methods are evolving
is crucial for regulating and optimizing these
technologies for patients.
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Classification of Dermatological Diseases
Using Clinical Images
The majority of studies implementing ML in
dermatology focus on classifying skin lesions
for a variety of diseases, including melanoma,
non-melanoma skin cancer (NMSC), psoriasis,
atopic dermatitis, onychomycosis, and rosacea.
These studies primarily rely on CNN for image
recognition and classification. Initially, a pre-
trained CNN (i.e., AlexNet) was only used to
extract features, and these features were then
classified by a more simplistic ML algorithm,
such as k-nearest neighbors or SVMs [24–26].
Currently, most CNNs can both extract features
and classify images through end-to-end
learning.
Melanoma
Melanoma is the fifth most common invasive
cancer in the USA, and its incidence is increas-
ing around the world [27, 28]. Melanomas are
also responsible for the vast majority of skin
cancer-related mortalities [28]. Skin cancer is
screened visually with a total body skin exami-
nation. Unfortunately, data from the National
Health Interview Survey indicate that screening
rates are remarkably low (16% in men and 13%
in women) [29]. Consequently, the first deep
learning algorithms focused on classifying
melanoma to address low screening rates and
increase access. One of the first milestone
studies to classify malignant melanoma with
notable accuracy was that of Esteva et al. in
2017 [30]. This historic study used a CNN called
Google Inception V3 that was previously pre-
trained on 1.28 million images of general
objects. Using transfer learning, the authors
trained the algorithm using 129,450 dermo-
scopic and clinical images. This was the first
classifier to show comparable accuracy to der-
matologists when classifying keratinocyte car-
cinoma versus seborrheic keratosis, and
malignant melanoma versus benign nevi. The
CNN achieved 72.1% accuracy while two der-
matologists achieved 65.56 and 66% accuracy,
respectively. The CNN achieved an overall AUC
of[ 91%, which was similar to the average
output predications of 21 dermatologists. Many
studies since then have leveraged transfer
learning to classify lesions into a number of skin
cancer classes and determine the probability of
malignancy; these studies showed comparable
accuracy, AUROC, sensitivity, and/or specificity
to board-certified dermatologists or dermatolo-
gists in training [19, 31–39]. It is also important
to note the average dermatologist’s diagnostic
accuracy (e.g., sensitivity and specificity) when
evaluating ML models for general screening.
The authors of a systematic review of prospec-
tive studies note that regarding the diagnostic
accuracy of melanoma, the sensitivity for der-
matologists was 81–100% and that for primary
care physicians (PCPs) was 42–100% [40]. While
none of the studies in the review reported the
specificity for dermatologists, one study did
report specificity for PCPs to be 98%. For biopsy
or referral accuracy, the sensitivity for derma-
tologists and PCPs ranged from 82 to 100% and
from 70 to 88%, respectively, while the speci-
ficity for dermatologists and PCPs ranged from
70 to 89% and from 70 to 87%, respectively
[40]. Therefore, ML models demonstrating
similar diagnostic and biopsy/referral accuracy
may prove useful for general screening of
melanoma.
Studies by Brinker and colleagues have
demonstrated that CNNs can exhibit superior
sensitivity and specificity in melanoma classifi-
cation as compared to board-certified derma-
tologists and dermatologists in training [41, 42].
In one of their studies, these researchers used
transfer learning on a pretrained ResNet50 CNN
and trained it with 4204 biopsy-proven images
of melanoma and nevi (1:1). They also asked
144 dermatologists (52 board-certified and 92
junior dermatologists) to evaluate 804 biopsy-
proven dermoscopic images for melanoma ver-
sus nevi. The trained CNN achieved a higher
sensitivity (82.3 vs. 67.2%) and specificity (77.9
vs. 62.2%) than both the board-certified and
junior dermatologists. Although these findings
are promising, images from the same overall
dataset were used for both training and valida-
tion. This algorithm has also not been exter-
nally validated; therefore, it is unclear whether
these results are generalizable to other datasets.
This limitation is discussed by the authors who
suggest that future research could fine-tune the
370 Dermatol Ther (Heidelb) (2020) 10:365–386
CNN with a small sample of new images before
being applied to new datasets. Nevertheless,
further validation in prospective clinical trials
in more real-world settings is necessary before
claiming superiority of algorithm performance
over dermatologists. While most of these stud-
ies pitted artificial intelligence algorithms
against dermatologists, a recent study by Hekler
et al. [43] found that combining human and
artificial intelligence accomplishes a better
classification of images as compared to only
dermatologists or only classification by a CNN
[43]. The mean accuracy increased by 1.36%
when dermatologists worked together with ML.
While the results were not statistically signifi-
cant, it is an important step toward finding the
best way to maximize combining human and
artificial intelligence.
A few studies have also integrated clinical
metadata, such as patient demographics (i.e.
age, gender, etc.), with images of lesions and
have shown that a classifier based on both
patient metadata and dermoscopic images is
more accurate than a classifier based only on
dermoscopic images [32, 44]. Other studies have
combined dermoscopic images with macro-
scopic images [45] or with a sonification layer
[39] to increase the accuracy of its classifier.
When diagnosing unknown skin lesions, clini-
cians typically do not only visually inspect the
skin, but they simultaneously take into account
many points of clinical data, including patient
demographics, laboratory tests, etc. Accounting
for clinical patient data into future CNNs has
the potential for creating more accurate algo-
rithms and significant biomarkers.
It is difficult to validate the results of many
of these studies since their algorithms are not
publicly available. However, the authors of one
study made their algorithm easily accessible
online [31]. In this study, Han et al. transferred
learning with the pretrained CNN, the Micro-
soft ResNet-152 model, to train 19,398 images
from four databases of Asian patients and then
validated the model on both Asian and Cau-
casian patients for 12 diagnoses, including basal
cell carcinoma, squamous cell carcinoma,
intraepithelial carcinoma, and melanoma. The
AUCs for the corresponding diseases were all
comparable to those of 16 dermatologists.
However, the AUCs for basal cell carcinoma
(0.96 for the Asian dataset vs. 0.90 for the
Caucasian dataset) and melanoma (0.96 for the
Asian dataset vs. 0.88 for the Caucasian dataset)
were slightly lower for the Caucasian dataset
than for the Asian dataset [31], demonstrating
that the accuracy of algorithms can be affected
by differences in patient ethnicity. Both clinical
presentation and prevalence of diseases can
differ between ethnicities. For example, basal
cell carcinoma presents with a brown, glossy
pigmentation in 75% of basal cell carcinomas in
Japanese patients but in only 6% of basal cell
carcinomas in Caucasian patients [46]. In addi-
tion, melanomas have a low incidence in Asian
populations and are more common in Cau-
casian populations [46]. Asians are more likely
to develop a rare subtype melanoma called acral
lentiginous melanoma, which accounted for
69.6% of melanomas in the Asian dataset that
trained Han et al.’s algorithm [31, 46]. These
algorithms need to be trained and validated in
more diverse population sets to better reflect the
world’s population. Most algorithms are trained
on either Caucasian or Asian patients.
The algorithm published by Han et al. [31] is
one of the few that are publicly available and,
consequently, Navarrete-Dechent et al. were
able to evaluate its generalizability [47]. These
authors tested the algorithm with 100 biopsy-
proven, high-quality images from the Interna-
tional Skin Imaging Collaboration Archive; all
100 images were lesions from Caucasians in the
USA. They found that the top-1 error rate was
71% and the top-5 error rate was 42%. Although
the sample size of the images tested by Navar-
rete-Dechent et al. [47] was small, these findings
suggest that the sensitivity of the algorithm was
significantly lower than had been presented in
the original publication [31]. It is known that
published algorithms may underperform in less
than ideal conditions or when validated
through external testing. Therefore, just as with
new drug treatments and other biomedical
technologies, it is crucial to require more
external testing and validation of these
algorithms.
There has been only one prospective trial
examining the accuracy of a deep learning
algorithm for the accurate diagnosis of
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melanoma [48]. This study used the artificial
intelligence algorithm Deep Ensemble for
Recognition of Malignancy, developed by Skin
Analytics Ltd. (London, UK), to identify mela-
noma in dermoscopic images of lesions taken
with a smartphone and digital single-lens reflex
(DSLR) camera [48]. This project trained the
algorithm on dermoscopic images of biopsy-
proven and control lesions from 514 patients.
The inclusion of controls, or lesions believed to
be benign, was useful because the algorithm
maintained a high specificity. Most studies have
only been trained on datasets of lesions already
considered to be suspicious of melanoma,
which creates a biased dataset. The algorithm
achieved comparable AUROCs for biopsied
lesions and all lesions captured with Apple
iPhone 6 s images (90.1% for biopsied lesions
and 95.8% for all lesions), Samsung Galaxy S6
images (85.8% for biopsied lesions and 86.9%
for all lesions), and DSLR camera images (86.9%
for biopsied lesions and 91.8% for all lesions).
Specialists achieved an AUROC of 77.8% for all
lesions; however, the type of specialist and the
credentials of whether the specialist was board-
certified in dermatology were not specified.
Previous studies have found significant differ-
ences in the accuracy of classification of malig-
nant versus benign melanoma between PCPs
and dermatologists.
It is also important to be aware of potential
diagnostic confounders before implementing
these CNNs on a large scale. Artifacts, such as air
bubbles, skin hairs, or ruler markers, have been
noted to disrupt automated melanoma detec-
tion [49]. Suspicious lesions are routinely
marked with gentian violet surgical skin mark-
ers. Ink markings have been found to be more
prevalent among malignant lesions than among
benign lesions in test image datasets [47], and it
has been reported that ink markings can sig-
nificantly interfere with the CNN’s correct
diagnosis of nevi by increasing both the likeli-
hood of the lesion being a melanoma and the
false-positive rate of the classifier [50]. There-
fore, it is recommended to avoid ink markings
in dermoscopic images analyzed by a CNN.
Such confounders are difficult to identify
because ML algorithms cannot necessarily
explain their outputs.
Non-Melanoma Skin Cancer
New studies have focused on classifying NMSCs
or skin cancers that occur on specific regions
(i.e., lips or face). NMSCs, such as basal cell
carcinoma and squamous cell carcinoma, are
the most common cancers in Caucasians [51].
Diagnosing NMSC is a complex classification
problem because the differential diagnosis for
NMSC includes benign and malignant neo-
plasms, cysts, and inflammatory diseases. In
contrast, determining the diagnosis of mela-
noma versus benign pigmented nevus is a sim-
pler binary classification problem. In 2019,
Tschandl et al. [52] demonstrated that a com-
bined CNN (cCNN) can classify dermoscopic
and clinical images of nonpigmented lesions on
par with experts, namely 95 human raters of
whom 62 were board-certified dermatologists.
The authors combined the outputs of two
CNNs, one trained with dermoscopic images
and the other with clinical images. While the
AUROC of the trained cCNN was higher than
that of the human raters (0.742 vs. 0.695), the
cCNN did not achieve a higher percentage of
correct specific diagnoses when compared with
experts (37.3 vs. 40%). The classifier exceeded
the accuracy of human raters for common
nonpigmented skin cancers such as basal cell
carcinoma, actinic keratoses, squamous cell
carcinoma, and keratoacanthoma, but the clas-
sifier was not as accurate as human raters for
rare malignant nonpigmented lesions such as
amelanotic melanoma and benign nonpig-
mented lesions. This study is an important
example of how the data input into a CNN can
determine the accuracy of the CNN’s outputs, as
the CNN used in this study was trained on very
few images of the rare nonpigmented lesions.
Tschandl and colleagues admit that this algo-
rithm is not ready to be implemented in the
clinic, but the results of the study do demon-
strate that CNNs are capable of more complex
diagnoses and call for the collection of more
dermoscopic and clinical images of rare malig-
nant lesions. Marka et al. [3] carried out a sys-
tematic review of 39 studies on the automated
detection of NMSC and found that most studies
report model performance greater than or equal
to the reported diagnostic accuracy of the
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average dermatologist, but that relatively few
studies have presented a high level of evidence.
Some skin disorders occur more frequently or
exclusively on particular areas of the skin. For
example, many skin cancers occur on sun-ex-
posed areas such as the face or neck. Early
screening and detection of carcinomas that
occur on the face is crucial considering the sig-
nificant impact on quality of life and cosmetic
disfiguration if diagnosis is delayed. The tar-
geting of specific regions where skin cancers
occur more frequently has been explored in two
very recent studies [53, 54]. In one of these
studies, Cho et al. [53] focused on classifying lip
diseases at a similar level to dermatologists [53].
The CNN performed on par with dermatologists
and outperformed non-dermatologists in clas-
sifying malignant lip diseases. In the other
study, a more recent study by Han et al. [54],
R-CNNs were used to detect keratinocyte cancer
on the face [54], such that an R-CNN was used
to detect the location of the lesion and a tradi-
tional CNN was used to classify the lesion. The
R-CNN generated 924,538 possible lesions from
182,348 clinical photographs. The CNN was
trained on 1,106,886 image crops of the possi-
ble lesions. The authors reported an AUC of
0.910, sensitivity of 76.8%, and specificity of
90.6%. Again, the combined performance was
on par with dermatologists and outperformed
non-dermatologists. R-CNNs have been used in
fracture detection in radiology [55] and the
detection of the nail plate in onychomycosis
[56]. Algorithms could potentially detect and
diagnosis skin cancer without any preselection
of suspicious lesions by dermatologists.
Other Dermatological Diseases
Deep learning algorithms have also been
implicated in classifying other important der-
matological diseases. Similar to the accuracy of
CNNs used to classify melanomas, a study using
a CNN for psoriasis achieved an AUC of 0.981
and outperformed 25 Chinese dermatologists.
However, this model was limited to classifying
psoriasis located on large areas of exposed skin
due to the low quality and lack of scalp and nail
psoriasis images. This is a notable limitation
considering that the incidence of scalp psoriasis
is 45–56% and nail psoriasis is 23–27% among
psoriatic patients [57]. CNNs have been created
for other diseases, such as atopic dermatitis [58],
onychomycosis [56], and rosacea [59]. To clas-
sify onychomycosis, Han et al. [56] used a
R-CNN to generate a training datasets of 49,567
images of nails and found that a combination of
their datasets performed better than
dermatologists.
When compared to the number of studies on
skin cancer, there is still a significant shortage of
research conducted on classifying other types of
cutaneous diseases. These diseases may be
harder to classify because of greater clinical
heterogeneity (i.e., atopic dermatitis) [60], the
numerous subtypes (i.e., psoriasis), or more
variance in severity. Therefore, some studies
have focused on assessing specific features that
contribute to the severity of a disease. For
example, for psoriasis, dermatologists use the
Psoriasis Area and Severity Index (PASI) as the
gold standard to assess severity based on body
surface area involved, erythema, induration,
and scaling. ML models have been developed to
singly assess body surface area [61, 62], scaling
[63], induration/color [64–67], and erythema
only [68] in patients with psoriasis.
Dermatopathology
Deep learning algorithms are useful for classi-
fying images of lesions and histopathological
images. Advancements in digital pathology,
such as greater computing power and cheaper
data storage, have facilitated whole-slide imag-
ing. Whole-slide images allow entire high-reso-
lution slides to be stored permanently in a
digital format, making it easier to classify these
images using an algorithm. The complexity of
examining histopathology was first captured in
one study that developed a framework for an
unsupervised model to identify learned features
of basal cell carcinoma histopathology [69].
Unsupervised models are not yet frequently
used in medicine and do not require the input
of a clinician to label images for training the
model. The unsupervised learning model per-
formed with an AUROC of 98.1% [69]. How-
ever, with this approach, explanations for why
certain patterns and features chosen by the
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algorithm that discriminate between cancer and
healthy tissue are not always apparent. In some
cases, patterns discovered that are thought to be
specific for cancer actually identify cell prolif-
eration patterns seen in healthy tissue [69].
Therefore, more recent studies have relied on
supervised learning, in which a der-
matopathologist labels images to help train the
model [70, 71]. These studies highlight the
importance of the dermatopathologist in creat-
ing models to classify melanocytic lesions.
Models trained with image curation done by a
dermatopathologist were found to be 50% more
accurate and to take significantly less time to
train [70]. While most studies have focused on
using CNNs to classify whole-slide images, one
study has reported that basal cell carcinoma can
also be identified by using microscopic ocular
images (MOIs) of histopathological tissue sec-
tions [72]. MOIs are images taken on a smart-
phone equipped with a microscope eyepiece. In
that study, using transfer learning onto a CNN,
the authors study achieved an AUC comparable
to classification using whole-slide images [72].
Hekler and colleagues claimed that a CNN
which they tested outperformed 11 pathologists
in the classification of histopathological mela-
noma images [73]. In this study, 695 lesions
were classified by one expert histopathologist
using tissue slides stained with hematoxylin
and eosin. These slides were randomly cropped,
producing 595 images to train the algorithm
and 100 images to validate the algorithm. A
questionnaire with 100 randomly cropped
images was sent out to dermatologists, with the
results showing that 157 dermatologists
achieved a mean sensitivity of 74.1% and
specificity of 60%. At a mean sensitivity of
74.1%, the CNN achieved a mean specificity of
86.5%. The 157 dermatologists ranged from
junior to chief physicians. Chief physicians had
the highest mean specificity of 69.2% and a
mean sensitivity of 73.3%. At the same mean
specificity of 69.2%, the CNN had a mean sen-
sitivity of 84.5% [73].
However, in a reply, Ge´raud et al. [74] cau-
tion us to evaluate these studies with the same
metrics that we would use on other double-
blind peer-reviewed clinical trials or statistical
analyses [74]. These authors point out three
problematic limitations to the methods of
Hekler and colleagues’s paper. The first limita-
tion was that dermatopathologists were only
given 20 min to assess 100 images (12 s per
image), which is unrealistic in a clinical setting.
In a survey of dermatopathologists, more than
70% of dermatopathologists noted that the
quality and clarity of clinical information has a
‘large’ impact on their diagnostic confidence
and diagnostic accuracy, and some 44.7% of
respondents spent 30 min or more searching for
clinical information to assist with their
histopathological interpretation [75]. Future
research could use natural language processing
to comply relevant clinical information for each
set of histopathological images to reduce the
time spent searching for clinical information.
A second major limitation was that only one
histopathologist labeled the images to train the
ML model. Between histopathologists there can
be 25–26% discordance between diagnoses for
cutaneous melanoma and benign lesions [76].
Given this possibility of a significant amount of
disagreement between histopathologists, hav-
ing only one histopathologist label the images
used to train the model will magnify both the
accuracy and mistakes of that one histopathol-
ogist. Ge´raud et al. [74] suggest that studies
should include a larger cohort of images that are
labeled by at least three dermatopathologists.
Finally, a major limitation was that cropped
images only allow a small, random portion of
the lesion to be analyzed. Dermatopathologists
make diagnoses by examining the entire
lesion—not by examining only a small part of
the lesion. Ge´raud et al. [74] found that 15% of
the images used in the trial had no recognizable
melanocytic lesion whatsoever, which indicates
that these images only contained perilesional
normal skin tissue. Hekler et al. [77] also
released a similar study a few months earlier
with the same methods and model, claiming
that their models achieved pathologist-level
classification of histopathological melanoma
images, but this study still has the same pitfalls.
Most ML methods used to classify
histopathology have focused on skin cancer,
but there are early studies starting to work on
classifying other diseases. CNN can differentiate
dermis from epidermis in the histopathology of
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psoriasis lesions [78]. This is the first step toward
developing a ML solution for automatic seg-
mentation and diagnosis of psoriasis pathology.
Further research will need to go beyond this
basic segmentation and find more specific fea-
tures, such as detecting changes in the epider-
mis and the presence of immune and nucleated
cells.
Mobile Applications and Personal
Monitoring Devices
Mobile applications and personal monitoring
combined with ML algorithms hold great
potential due to their portability and conve-
nience. Melanoma screening through a mobile
application could ultimately increase the
accessibility of screening, especially in rural
areas with limited availability to dermatologists.
There are currently two types of mobile appli-
cations for melanoma screening: (1) store-and-
forward teledermatology and (2) automated
smartphone apps. The store-and-forward teled-
ermatology applications send pictures taken by
the patient to a remote dermatologist for eval-
uation. In contrast, automated smartphone
apps use a ML algorithm to determine the
probability of malignancy on the spot without
consultation from a dermatologist. In one sur-
vey, 70% of the patients using a store-and-for-
ward teledermatology program stated they
would not have seen a dermatologist without
the teledermatology program, indicating that
these applications can significantly impact
outreach [79]. It is important to note that these
applications are not a replacement for a face-to-
face consultation, especially since patients may
miss key lesions without a full body examina-
tion. The authors of a 2018 systematic review
report that the sensitivity of these automated
applications can range from 7 to 87% and that
there is an overall lack of evidence regarding the
safety for using these automated smartphone
applications [80]. As of 2018, none of the
automated smartphone applications for mela-
noma screening had been approved by the US
FDA. Since the publication of the last systematic
review of smartphone applications, a study on a
smartphone application called SkinVision
reported improved results for an algorithm
trained on more than 130,000 images by more
than 30,000 users [81]. This algorithm achieved
a higher sensitivity (95.1 vs. 80.0%) and similar
specificity (78.3 vs. 78%) than previously
reported [81, 82]. However, these results should
still be taken with caution given the lower
specificity compared to other experimental
deep learning melanoma classifications. The
lack of regulation of these applications and
potential for false negative/positives makes
these applications not adequate for patient use
at the present time. In the future, use of these
applications under careful physician consulta-
tion could allow for patients to better commu-
nicate with their healthcare professionals about
their skin concerns.
Data from personal monitoring devices can
also be useful in dermatology for quantifying
pruritus [83] or tracking skin over time [84].
One scientific method for assessing pruritus is
through video recording of patients, which is
tedious and not practical outside an experi-
mental setting [85]. Using a ML algorithm to
analyze data from a wrist actigraphy device to
quantify nocturnal scratching could lead to the
creation of novel therapies for atopic dermatitis
and other pruritic disorders [83].
Facilitating Large-Scale Epidemiology
Research
‘‘Big data’’ is defined by immense and complex
datasets for which traditional data processing
methods may be inadequate. These large data-
sets can derive from electronic medical records
(EMR), insurance claims, the internet, mobile
applications, personal monitoring devices, and
omics databases. Big data in dermatology pre-
sents a promising hypothesis-generating
framework to conduct research by identifying
unseen patterns within the data [1]. ML is the
perfect tool to analyze and harness the power of
this enormous amount of information. This
section will evaluate the use of ML in large
datasets for epidemiology applications and for
understanding patient experiences.
Using EMR data, ML has been used to
explore electronic health record-phenotyping
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[86–88], to conduct population-based analysis
[89], and to evaluate patient experiences [90].
NLP has been used to analyze EMR with the aim
to identify atopic dermatitis. This method is
useful for phenotyping patients for a genome-
wide association study. Previous atopic der-
matitis phenotyping done by human reviewers
of EMR had very high positive predictive value
(95.2%) but low sensitivity (8.7%), which lim-
ited the number of patients included [91]. Using
the ML algorithm for atopic dermatitis pheno-
typing, they achieved a similar positive predic-
tive value of (84.0%) with a much higher
sensitivity (75.0%), confirming that this
approach may be effective for developing phe-
notype algorithms. ML methods can also be
used to phenotype rare diseases, such as sys-
temic sclerosis in EMR data. One study found
that the highest performing ML methods to
phenotype systemic sclerosis incorporated clin-
ical data with billing codes [88]. Another study
used NLP to develop the first population-based
estimates of melanocytic lesions from EMR
pathology reports [89]. Further research can use
NLP to explore the epidemiology of other
cutaneous diseases using EMR. NLP can be used
on other sets of unstructured data. In one study,
social media data on Reddit were analyzed using
NLP to evaluate dermatology patient experi-
ences and therapeutics [90]. An examination of
176,000 comments suggested the utility of
social media data for dermatology research and
engagement with the public.
Machine Learning and Precision Medicine
The convergence of ML and stores of big data
has fueled the acceleration of the possibilities
for precision (also known as personalized or
individualized) medicine. The aim of precision
medicine is to develop targeted treatments
based on data from multi-omics platforms or
other phenotypic or psychosocial characteris-
tics to improve clinical outcomes and reduce
unnecessary side effects for those less likely to
respond to a certain treatment [92]. Studies not
using ML have taken the first steps toward pre-
cision medicine in dermatology by identifying
new genetic biomarkers and showing
differential response to therapy based on these
biomarkers. However, by harnessing the power
of ML, millions of datapoints can be analyzed,
thereby expanding the power of its predictive
results. Furthermore, genetic biomarkers can be
discovered faster than previously possible. Here
we discuss in more detail research being con-
ducted on the following cutaneous diseases:
psoriasis, psoriatic arthritis, and skin cancer.
Psoriasis
Despite the large amount of clinical trial data
on the efficacy of 11 FDA-approved biologics,
choosing a biologic for a patient is still based on
trial and error. It often takes 12–16 weeks for a
clinical response to be meaningful, and the
efficacy of the drug can range between a 30 and
80% success rate [93]. This creates an ‘‘assess-
ment gap’’ between a patient’s response to a
treatment that may in part be biologically
determined and when a response can be clini-
cally determined. Changes in biopsy or gene
expression profiles can show an improvement
and response to treatment faster than clinical
improvement. Therefore, ML can address this
assessment gap by predicting the long-term
outcomes of biologics in psoriasis patients.
Several studies have created ML prediction
models to determine the long-term treatment
response to biologics [93–96]. The first study to
assess this gap created two ML models to
examine gene expression data from skin biop-
sies [93]. The models predicted the PASI 75
response (i.e., a C 75% improvement in PASI
score from baseline) after 12 weeks of treatment
by evaluating the molecular profile of the short-
term (2–4 weeks) treatment. Both of these
models predicted the PASI 75 response with
high accuracy (AUC[0.80) and decreased the
psoriasis assessment gap by 2 months. Assess-
ment of baseline samples of gene expression
from skin biopsies may also be able to predict a
patient’s response to biologic therapies, a strat-
egy which was previously thought of as unre-
aliable [94]. Another study used multi-omics to
examine patients with severe psoriasis on etan-
ercept and found indications of treatment
response in genes and pathways associated with
tumor necrosis factor (TNF) signaling and the
major histocompatibility complex [94].
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Although the assessment of gene expression
data from skin biopsies is a promising method
to predict treatment response, skin biopsies are
still invasive and expensive. To address this
issue, Tomalin et al. [95] created a ML predictive
model from blood biochemical measurements
rather than skin biopsies. These authors mea-
sured the longitudinal profiles for 92 inflam-
matory and 65 cardiovascular disease proteins
at baseline and 4 weeks following the respective
treatment. The accuracy of the prediction of the
12-week efficacy endpoint following treatment
with tofacitinib or etanercept was AUROC 78%
and AUROC 71%, respectively. Interestingly,
simple models based on PASI scores performed
better than the blood predictive model, which
indicates that future studies may need to mea-
sure more proteins. A very recent study used six
different ML models based on basic health
information (i.e., drug discontinuations,
adverse events, etc.) to predict long-term
response to treatment [96]. The best model of
these authors predicted treatment outcomes
with 18% classification error, demonstrating the
utility of basic clinical information. In addition
to identifying the treatment response for pso-
riasis, ML models can also discover potential
off-label treatments for psoriasis, atopic der-
matitis, and alopecia areata [97]. This model
uses a combination of an unsupervised word
embedding model summarized drug informa-
tion from over 20 million articles and applica-
tion of classification of disease ML models to
identify potential drugs for immune-mediated
cutaneous diseases.
One step toward the effective treatment for
psoriasis is identifying the predictors of disease
and its co-morbidities. Psoriasis is associated
with an elevated risk of cardiovascular disease.
While coronary plaques can be characterized
through coronary computed tomography
angiograph, identifying potential risk factors is
important for predicting prospective cardiac
events. A recent study used ML to identify top
predictors of non-calcified coronary burden in
psoriasis [98]. These authors identified that
obesity, dyslipidemia, and inflammation are
important comorbidities/risk factors in
atherosclerosis.
Psoriatic Arthritis
Approximately 25% of patients with psoriasis
also develop chronic inflammatory arthritis
called psoriatic arthritis [99]. There is currently
no method to predict the development of pso-
riatic arthritis in a patient with only psoriasis
before symptoms appear. ML could be useful in
developing a quantitative assessment for psori-
atic arthritis risk among psoriasis patients based
on underlying genetic differences. Using data
from over 7,000 genotyped psoriatic arthritis
and psoriasis patients, Patrick et al. 2018 iden-
tified 9 new loci for psoriasis or its subtypes
[100]. They used ML methods to differentiate
psoriatic arthritis from psoriasis based on 200
genetic markers and achieved an AUROC of
0.82 [100]. This is the first study to show a
robust prediction of psoriatic arthritis using
only genetic data and presents the first step
toward a personalized approach to psoriatic
arthritis management.
Skin Cancer
Machine learning has been employed to
develop cancer risk models for melanoma [101]
and NMSC [102]. The dataset used to create the
risk model of melanoma was unique because it
encompassed over four million dermatology
patients in the USA from a cloud-based derma-
tology-specific EMR called Modernizing Ana-
lytics for Melanoma [101]. Given the vast size of
the data, the authors used a hybrid method of
distributed computing (using multiple com-
puters to maximize efficiency) and nondis-
tributed computing (using one computer) to
analyze the data. The distributed computing
method was used for collecting and formatting
the data and nondistributed computing was
used for ML. A good example of how ML and big
data can be used to examine a novel hypothesis
is a study done by Roffman et al. in 2018 [102].
While ultraviolet radiation exposure and family
history are major associated risk factors for
NMSC, these authors aimed to create an ANN to
predict personal NMSC risk solely based on 13
parameters of personal health data: gender, age,
basal metabolic index, diabetic status, smoking
status, emphysema, asthma, Hispanic ethnicity,
hypertension, heart diseases, vigorous exercise
habits, and history of stroke. Given that the
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model performed with an AUROC of 0.81
without any evaluation of the major associated
risk factors or images, it has the potential for
improving the diagnosis and management of
NMSC. Another study predicted the likelihood
of the development of NMSC by analyzing two
million randomly sampled patients from the
Taiwan National Health Insurance Research
Database [103]. A CNN analyzed 3 years of
clinical diagnostic information [i.e., Interna-
tional Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) diagnosis and
procedure codes and prescriptions; https://
www.cdc.gov/nchs/icd/icd9cm.htm] and tem-
poral-sequential information (i.e., dates of
clinical visits and days of prescriptions) to pre-
dict the development of NMSC of a given
patient within the next year and achieved an
AUROC of 0.89 [103].
DISCUSSION
In this review, we have summarized the basic
principles of ML and its current applications in
dermatology. We have reviewed that ML has
numerous potential applications in the derma-
tologist’s workflow from diagnosis to treatment.
Based on the literature, we have identified five
areas of applications of ML in dermatology
(Fig. 2).
All five areas have benefited from the advent
of powerful deep learning algorithms that can
analyze large datasets. In the first area, deep
learning algorithms are helpful for identifying
melanoma, NMSC, and other dermatological
diseases from dermoscopic, DSLR, and smart-
phone images. Classification algorithms for
melanoma and NMSC are the most well-studied
ML algorithms in dermatology and can poten-
tially address low skin cancer screening rates by
increasing access. Classification of other dis-
eases is still in its nascency and will likely
involve more complex algorithms to grade dis-
ease severity and produce accurate differential
diagnoses. In the second area, deep learning to
classify histopathology is also still in its early
stages and has underscored the importance of
involving dermatologists and dermatopatholo-
gists in the development of ML studies, as the
models perform better with image curation
done by dermatopathologists. Most of these
studies were published without a dermatologist
listed as an author, which suggests that more
dermatologists should be involved in the
development of these ML models. In the third
area, mobile applications for classifying lesions
and skin cancer are unregulated and are not
currently not sufficiently accurate or sensitive
to serve as useful screening tools. Once classifi-
cation algorithms are more accurate and have
been properly clinically validated, mobile
applications can disseminate these screening
tools to populations in need. In the fourth area,
ML can analyze large datasets, such as EMR data
and insurance claims, that are useful for epi-
demiological studies. Lastly, ML can be useful as
a tool to predict treatment response and sup-
plement diagnosis for patients with psoriasis,
psoriatic arthritis, and skin cancer.
Machine Learning: Limitations
and Considerations
Before any of these technologies are imple-
mented in a real-life setting, it is critical to dis-
cuss considerations and limitations for the
development of these technologies (Fig. 3).
These algorithms are useful for making specialty
diagnoses more accessible in areas where there
is a paucity of dermatologists. However, the
accuracy of these algorithms is hard to deter-
mine when they are used without any physician
input. A major limitation of ML is that it is hard
to explain how these algorithms come to their
conclusions. A ML algorithm can be compared
to a black box that takes in inputs and produces
outputs with no explanation of how it produced
the outputs. If an algorithm misdiagnoses a
malignant lesion, the algorithm cannot explain
why it chooses a certain diagnosis. While the
outputs can be helpful, if the model is unable to
explain to a patient why it diagnosed a lesion as
malignant versus benign or how it chose a
particular therapy, it is potentially dangerous
and problematic for the patient. Physician
interpretation is necessary to explain why a
diagnosis or treatment should be chosen. In
addition to the black box nature of these
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algorithms, ML is also prone to the maxim
‘‘garbage in, garbage out.’’ This maxim indicates
that the quality of the dataset input determines
the quality of the output. Therefore, if these
images’ inputs are poorly labeled, then the
algorithm’s outputs will reflect these
inaccuracies.
Fig. 2 Applications of machine learning in dermatology.
Flowchart demonstrating the various sources of data in
dermatology, machine learning models, and potential
applications. Icons were created with the web-based
program BioRender (https://biorender.com)
Fig. 3 Limitations of machine learning. Icons were created with the web-based program BioRender (https://biorender.com)
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Regarding the impact of bias on clinical
decisions for patient care, it is also crucial to
consider how bias in algorithms can potentially
impact millions of patients. As noted earlier,
artifacts, such as pen markings, air bubbles, or
hairs, can interfere with the algorithm’s correct
diagnosis by falsely associating these markings
with the prevalence of a disorder [48]; this
limitation reinforces the black box nature of
ML. The outcomes decided by the algorithm are
not always based on clinical evidence. There-
fore, ML appears to be a useful tool to supple-
ment physician diagnosis and treatment, but it
should not replace decisions made by physi-
cians based on clinical evidence.
As a field, we should work to make this
technology more accessible and be aware of
other potential biases that could exacerbate
current health disparities. Almost all of these
studies reported in this review focus on images
and data from Caucasian patients from North
America and Europe, with only a few studies
focusing on images of Korean, Chinese, or
Japanese patients in Asia. It was even noted that
studies trained on images of Asian patients
performed worse on Caucasian patients [31, 47].
Applying algorithms trained on images of fair
skin could be inaccurate on skin of color as
many cutaneous diseases manifest differently in
skin of color; for example, psoriasis may appear
more violaceous and less red in individuals with
darker skin than in Caucasian patients. Early
screening of skin cancer could have a significant
benefit for patients with darker skin who cur-
rently experience more advanced disease and
lower survival rates due to delays in diagnosis
[104, 105]. Since ML models are still in their
nascency, we have the opportunity to improve
these studies by making sure this technology
can be inclusive to patients of all ethnic and
racial backgrounds.
Regulation and Liability in Machine
Learning
Given the myriad of applications of ML in der-
matology, it will be important for clinicians to
be involved in determining the appropriate
regulation for these devices. In the USA, any
changes or modifications to medical devices are
typically approved by the US FDA through a
supplement to premarket approval or as a new
510(k) submission. However, deep learning
algorithms update and change in real time as
they are exposed to more clinical examples and
experiences. Therefore, as the algorithms con-
tinuously update, the outputs could differ from
what was initially approved by the FDA.
Continuous software iterations in ML devi-
ces will require the development of more
specific regulatory approval than that used for
traditional physical devices. The first ML-based
software approved by the FDA was in 2018 for a
program that diagnosed diabetic retinopathy
without clinician interpretation. The FDA has
only authorized ‘‘locked’’ ML devices, meaning
that they do not continually learn or adapt the
algorithm in real time. In April 2019, the FDA
announced that it is working on a new regula-
tory framework for modifications to ML-based
software or ‘‘unlocked’’ ML algorithms [106].
This framework proposes a ‘‘predetermined
change control plan’’ that includes types of
anticipated modifications and the associated
methodologies being used to incorporate those
changes while managing risks to patients. This
proposal is not the final regulatory expectation
but is gathering input from a wide variety of
groups and individuals to draft appropriate
guidelines. Interestingly, Hwang et al. [107]
noted that 11 of the 14 devices approved by the
FDA between 2017 and 2018 were through the
510[k] pathway which only requires ‘‘substan-
tial equivalence’’ to an already-marketed device.
This means that these devices are deemed as
‘‘moderate risk’’ products and are not required
to have clinical testing. A lifecycle-based
framework for regulating ML-based software
will be important for ensuring the safety and
efficacy of these devices. In addition, all devices
should be evaluated in prospective clinical trials
and made publicly available in peer-reviewed
literature.
Another potential area of concern is the
uncharted territory of determining the liability
of using a ML device for an erroneous decision
in patient care. Currently, physicians are pro-
tected as long as they follow ‘‘standard of care,’’
but as ML becomes more accurate it may
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become the ‘‘standard of care’’ over previous
practices. According to Price et al. [108], the
safest way to use ML is to use it only as a con-
firmatory tool to support existing decision-
making processes and to check with individual
malpractice insurers. Physicians are likely to
influence how ML is used in practice and when
it should be applied in place of human decision.
CONCLUSIONS
Machine learning presents a tremendous
potential in dermatology, from diagnosis to
predicting more effective and safer treatments.
As this technology advances, dermatologists
will need to gain an understanding of how ML
works, along with when and how it should be
appropriately used in a clinical setting. While
ML methods are powerful, they are still similar
to previous clinical tools in that physician
interpretation is crucial for implementation in a
real-world setting. We should also be cognizant
of how potential biases can interfere with the
black box nature of these algorithms. It is also
important to make these technologies inclusive
of skin of color. Further research in ML should
be transparent by making algorithms and data-
sets available to the public for further validation
and testing. Before coming to market, rigorous
peer-reviewed prospective clinical trials should
be conducted. Overall, involving more derma-
tologists in the development and testing of ML
is imperative for creating useful and clinically
relevant technology.
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